Lunaphore founding team Déborah Heintze, Diego G. Dupouy, and Ata T. Ciftlik
Congratulations to our portfolio company Lunaphore for closing their second financing round of CHF 6 million. In 2015, Redalpine led Lunaphore’s initial funding round. Performance has been strong since and we were delighted to add to our commitment, together with new investors Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group.
Lunaphore develops a disruptive next-generation technology for cancer tissue diagnostics for laboratories and hospitals. The Swiss medtech company has closed this substantially oversubscribed financing round of CHF 6M in July after achieving all key milestones to date.
In the round, three new investors, Zühlke Ventures, Polytech Ecosystem Ventures and Occident Group joined, together with private investors. Existing investors, including Redalpine, also contributed a significant amount. The funds will pave the way for market access.
“We are glad to see the interest of new investors, as well as the strong confidence shown by our existing investors who increased their participation considerably,” says Dr. Ata Tuna Ciftlik, Founder and CEO of Lunaphore. “We believe that Zühlke Ventures’ engineering and industrialization expertise in similar spaces along with Polytech Ecosystem Ventures’ footprint in Silicon Valley support the execution of our strategy and strengthen our international network,” he adds.
Redalpine is very happy to hold a company of the caliber of Lunaphore in the portfolio. Dr. Michael Sidler, co-founding partner of Redalpine, states: “We are very pleased to see that Lunaphore’s strategy is well executed by the whole team. The impressive progress of the company has already generated solid interest from strategic key players. We are very excited about the prospects of Lunaphore!”
Redalpine congratulates the Lunaphore team on the achievements to date and we look forward to a continued successful collaboration.
For more information, please visit www.lunaphore.ch